The fact that the combination of chemotherapy plus anti-IL-10, 2′3’-cGAMP, and anti-PD-L1 was effective not only against ovarian cancer but also against lung cancer, which presents a completely different tumor microenvironment, suggests that this combination approach could potentially be employed in a variety of tumors that have not responded to adaptive immunotherapy alone to date. The gene discussed is IL10; the disease is lung cancer.